Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WR99210 is a synthetic small molecule belonging to the triazine class. It is primarily used as an experimental antifolate compound in research settings. The compound acts as a potent inhibitor of dihydrofolate reductase (DHFR), particularly targeting the DHFR enzyme from Plasmodium species (malaria parasites), while showing much lower affinity for mammalian DHFR. This selectivity makes it valuable in studies of malaria drug resistance and transgenic selection systems for Plasmodium and related protozoa. It is not approved for clinical use in humans or animals and is mainly supplied for laboratory research purposes[1][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WR99210.